Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Last updated: September 18, 2026 The FDA approved Ultragenyx’s Fayuvi for Sanfilippo syndrome type A on September 17, two days before its September 19 action
Last updated: September 17, 2026 Vera Therapeutics reported that Trutakna cut the risk of kidney disease progression 76% over two years in the ORIGIN 3
Last updated: September 16, 2026 Amgen presented at the Morgan Stanley Global Healthcare Conference on September 15 without naming an OCEAN(a) readout window or a
Last updated: September 15, 2026 The FDA approved Scholar Rock’s Isembyld (apitegromab) for spinal muscular atrophy 19 days ahead of its September 30 action date,
Last updated: September 14, 2026 AstraZeneca said September 12 that SERENA-4, the 1,371 patient first line trial of Etcamah (camizestrant) plus palbociclib, missed its primary
Last updated: September 11, 2026 The FDA paused new enrollment in Biohaven’s pivotal opakalim epilepsy trials on September 10 over a rodent metabolite finding, fifteen
Last updated: September 10, 2026 Bristol Myers Squibb’s GPRC5D CAR T arlo-cel met its registrational myeloma trial with response figures withheld, the FDA granted Bayer’s
Last updated: September 9, 2026 Novartis’ del-desiran missed its Phase 3 primary endpoint in myotonic dystrophy, the third pipeline blow in a week. Amgen fell
Last updated: September 8, 2026 Novartis’ pelacarsen missed the primary endpoint of the 8,323 patient Lp(a)HORIZON outcomes trial, Novo Nordisk stopped two Phase 3 ziltivekimab
Last updated: September 4, 2026 Akeso’s ivonescimab showed a statistically significant overall survival benefit over pembrolizumab monotherapy in the Chinese HARMONi-2 trial, with numbers withheld
